ISSI ROZEN, Chief Business Officer at the Broad Institute of Harvard and MIT, is responsible for partnering with the life sciences industry and venture investors and developing innovative scientific and business collaborations. He is also responsible for initiating and establishing new ventures around novel technologies and for licensing the institute’s intellectual property portfolio. He joined the Broad in 2011 after a career in the biotech industry. Before joining the Broad Institute, Rozen led corporate development at Resolvyx, a venture-backed biotech start-up. Before that, he headed the business analysis group at EMD Serono where he was responsible for evaluations of in-licensing and M&A opportunities as well as commercial analytics and forecasting for pipeline and commercial products. Issi is a co-founder of a number of biotech start-ups and is an accomplished jazz guitarist. He earned his M.B.A. at MIT’s Sloan School of Management.
Guru (CB Gurumurthy) received his BVSC (DVM) from Bangalore Veterinary College, India and MVSC & PHD in Veterinary Virology from Indian Veterinary Research Institute, with a Gold Medal distinction in MVSC, and an Executive MBA from University of Nebraska at Omaha. He is currently an Associate Professor of Developmental Neuroscience, Munroe Meyer Institute for Genetics and Rehabilitation at the University of Nebraska Medical Center. He is also the Director of the UNMC’s Mouse Genome Engineering Core Facility. His research interests are improving and development of novel genome engineering technologies. He is a co-developer of popular technologies such as Easi (Efficient additions with ssDNA-inserts)-CRISPR, CRISPR-first: PITT-next and GONAD (Genome Editing via Oviductal Nucleic Acids Delivery). Some of these technologies have already been adapted in many labs worldwide.
At a recent event, Maarten Goossens of Anterra Capital stated that "Now is the right time to invest in the animal health biotech space."
His five key areas of innovation to watch are:
Targeted gene editing
